Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 37, 2020 - Issue 5
Submit an article Journal homepage
178
Views
1
CrossRef citations to date
0
Altmetric
Articles

Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story

Lisa TricheMD Anderson Cancer Center, University of Texas, Houston, Texas, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-5016-7245
ORCID Icon,
Angela YarbroughMD Anderson Cancer Center, University of Texas, Houston, Texas, USA
,
Michael RothMD Anderson Cancer Center, University of Texas, Houston, Texas, USA
,
Anita YingMD Anderson Cancer Center, University of Texas, Houston, Texas, USA
&
Robert WellsMD Anderson Cancer Center, University of Texas, Houston, Texas, USA
Pages 375-379 | Received 30 Jan 2020, Accepted 26 Mar 2020, Published online: 29 Apr 2020

References

  • Tanizawa A. Optimal management for pediatric chronic myeloid leukemia. Pediatr Int. 2016;58(3):171–179. doi:10.1111/ped.12876.
  • Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346–357. doi:10.1002/ajh.25342.
  • Murthy GS, Atallah E. Treatment-free remission in CML: the US perspective. Curr Hematol Malig Rep. 2019;14(1):56–61. doi:10.1007/s11899-019-0496-8.
  • de Bruijn CMA, Millot F, Suttorp M, et al. Discontinuation of imatinib in children with chronic myeloid leukemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol. 2019;185(4):718–724. doi:10.1111/bjh.15826.
  • Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392–399. doi:10.1182/blood-2015-06-648667.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872–884. doi:10.1182/blood-2013-05-501569.
  • Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63(8):1332–1338. doi:10.1002/pbc.26028.
  • Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol. 2009;89(2):251–252. doi:10.1007/s12185-008-0251-8.
  • Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159(4):676–681. doi:10.1016/j.jpeds.2011.03.046.
  • Hobernicht SL, Schweiger B, Zeitler P, et al. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer. 2011;56(4):671–673. doi:10.1002/pbc.22945.
  • Walia R, Aggarwal A, Bhansali A, et al. Acquired neuro-secretory defect in growth hormone secretion due to imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia. Pediatr Hematol Oncol. 2019;37(2):99–108.
  • Chamoun K, Kantarjian H, Atallah R, et al. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single institution experience. J Hematol Oncol. 2019;12(1):1. doi:10.1186/s13045-018-0686-1.
  • Zadik Z, Estrov Z, Karov Y, et al. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission-a preliminary report. J Pediatr Endocrinol. 1993;6(1):79–83. doi:10.1515/jpem.1993.6.1.79.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.